8 Feb, 2019

New data on SpagoPix published in European Journal of Inorganic Chemistry

Study results show that the signal strength of SpagoPix is among the highest reported for MRI contrast agents and far higher than those of the clinically used gadolinium based contrast agents currently in clinical use.

The article, titled ”Characterization of a manganese-containing nanoparticle as MRI contrast agent”, is the result of a collaboration with researchers at the University of Turin led by professor Silvio Aime. The paper describes physicochemical studies where the signal strength of SpagoPix has been documented.

”We have shown that, overall, the per-manganese relaxivity of SpagoPix is among the highest reported for manganese-containing systems and far higher than those of the clinically used gadolinium based contrast agents”, the authors state.

The article is available at https://onlinelibrary.wiley.com/journal/10990682c.

Spago Nanomedical is currently preparing SpagoPix for clinical studies, starting in breast cancer patients.

For further information, contact Mats Hansen, VD Spago Nanomedical AB, +46 46 81188, mats.hansen@spagonanomedical.se.

Spago Nanomedical (Spotlight Stock Market, Stockholm: SPAG) develops nanomaterials for cancer diagnostics and therapy. The company´s development activities are primarily focused on the cancer selective MRI-contrast agent SpagoPix, and the Tumorad®-project for cancer selective radionuclide therapy of cancer. The business concept of Spago Nanomedical is to develop projects from explorative to regulatory preclinical or early clinical phase, and then out-license or enter partnership for continued development of the projects to market launch. Spago Nanomedical collaborates with well-established and reputable patent consultants to continuously strengthen the intellectual property protection of the projects.

SpagoPix is a nanoparticle-based contrast agent with manganese with potential to improve cancer diagnosis using magnetic resonance tomography (MRI). By offering high precision and superior enhancement of tumors and metastases in MRI-images, the chances of correct diagnosis increase. Improved MRI diagnostics increase the chances of effective treatment for the patient. SpagoPix is also free from gadolinium, an element that may cause unwanted side effects and has caused regulatory agencies to issue warnings or withdraw products from the market.

For further information, see www.spagonanomedical.se.


New data on SpagoPix published in European Journal of Inorganic Chemistry